[verwijderd] 13 april 2009 23:46 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT TrialSEATTLE, April 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. Those interested may access the call with the following information: Time: 9:00 AM ET/6:00 AM PT Date: April 14, 2009 Dial-in: 1-877-419-6594 (domestic) or +1-719-325-4855 (international) Webcast: www.dendreon.com (homepage and investor relations section)A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457-0820 for international callers; the conference ID number is 8182435. The replay will be available from 12:00 pm ET on April 14, 2009 until midnight ET on April 16, 2009. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com. About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com. SOURCE Dendreon Corporation www.dendreon.com Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 14:35 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study- Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival -- First Active Immunotherapy for Cancer to Prolong Survival -- Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting -- Company to Host a Conference Call Today at 9:00 AM ET -No specific data mentioned yet Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 15:04 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 +17 dollar+240% met 2mln volume zover na 4 minutne handel Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 15:32 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Fantastisch nieuws voor alle mannen! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 15:47 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:crackedtooth schreef:+17 dollar+240% met 2mln volume zover na 4 minutne handelAf en toe moet je geluk hebben.Gisteren, uit baldadigheid gekocht op 7 en vandaag op 20 eruit.Dat zijn leuke geintjes, al waren het maar 400 aandelen.mvg, waarom maar 400 vraag je je dan af, ipv feest te vieren. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 17:25 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Smullen!!www.blinkx.com/video/dendreon-shares-...P. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 17:49 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Een aangename verassing toen ik net op de computer keek. Ik heb ze een paar dagen geleden voor $6.75 gekocht. Dit is een opsteker! Zit er nog meer in? Ik had ze op $ 24 te koop staan maar dat is helaas net niet gehaald. Zou dat nog komen. Wie geeft een reactie? Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 17:53 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:domus muris schreef:Een aangename verassing toen ik net op de computer keek. Ik heb ze een paar dagen geleden voor $6.75 gekocht. Dit is een opsteker! Zit er nog meer in? Ik had ze op $ 24 te koop staan maar dat is helaas net niet gehaald. Zou dat nog komen. Wie geeft een reactie?Hier wordt een koopadvies met koersdoel van $25,- gegeven.seekingalpha.com/article/130863-dendr... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 18:02 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:Kieter schreef:[quote=domus muris]Een aangename verassing toen ik net op de computer keek. Ik heb ze een paar dagen geleden voor $6.75 gekocht. Dit is een opsteker! Zit er nog meer in? Ik had ze op $ 24 te koop staan maar dat is helaas net niet gehaald. Zou dat nog komen. Wie geeft een reactie?[/quote]Hier wordt een koopadvies met koersdoel van $25,- gegeven.seekingalpha.com/article/130863-dendr...O, maar ik ben met $ 24 ook wel redelijk tevreden. In ieder geval bedankt, Kieter. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 14 april 2009 21:30 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Gefeliciteerd allemaal, hoop dat Discovery Lab a.s. vrijdag ook een leuk sprongetje gaat maken! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 19 april 2009 16:40 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Nu ook goede cijfers mbt. vroege prostaatkanker.Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer Data presented at 100th Annual Meeting of the American Association for Cancer ResearchSEATTLE, Wa and DENVER, Co., April 19, 2009 -- Researchers from Dendreon Corporation (Nasdaq: DNDN) presented today data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE® (sipuleucel-T) induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APCs), a measure of potency, is a correlate of immune activation. P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate. Patients were randomized to PROVENGE or placebo following 3 months of hormone therapy. This study evaluated CD54 upregulation and peripheral immune responses in men enrolled in the trial. PROVENGE or placebo was administered at weeks zero, two and four. A treatment booster infusion of PROVENGE or placebo was offered after confirmed PSA >3.0ng/mL. Immune responses were measured pre-treatment, at weeks four and 13, and at four and 13 weeks following the booster infusion. At the week zero dose of PROVENGE, the expression of CD54 on APCs was upregulated 5.8 fold. At the week two dose, it was 10.1 fold, significantly increased from week 0 (p < 0.001). The increase in CD54 upregulation persisted at week four (10.7 fold) and at the time of the booster infusion (12.0 fold). There was an increase in cellular immune response between pre-treatment and week four (p < 0.001), which persisted through 13 weeks after the booster infusion (p < 0.001). The PROVENGE booster infusions occurred from 0.2 to 5.5 years (median 1.1 years) after the week four dose. Data is being presented in a session titled, "Cancer Vaccines: Human Studies" in a presentation titled, "Antigen presenting cell activation in sipuleucel-T and long-term immune responses in prostate cancer trial" today at 8:00 AM MDT at the 100th Annual Meeting of the Association for Cancer Research in Denver, Colorado. "We are encouraged to see that CD54 upregulation in APCs is maintained after boosting in men with androgen-dependent prostate cancer," said David Urdal, chief scientific officer of Dendreon. "This pattern of CD54 upregulation suggests that the first dose 'primes' the immune system for subsequent 'memory' responses and is consistent with that observed in our studies of men with androgen-independent disease where the cumulative CD54 upregulation dose correlated with survival. We also are encouraged by these data which suggest that the immune response generated by PROVENGE is durable for a year or more after initial treatment and that it can be maintained following boosting."Study Design The study, known as PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11, is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and biologic activity of PROVENGE in men with non-metastatic androgen-dependent prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate. A total of 176 patients at 19 sites in the United States were randomized two to one to receive PROVENGE or placebo following a three-month course of hormonal therapy. Patients were then followed with serial PSA measurements to evaluate the impact of PROVENGE on PSA and PSADT (PSA doubling time). At the time of biochemical progression, defined as a PSA of 3ng/mL or greater, men became eligible for one booster infusion of either PROVENGE or placebo in accordance with the treatment arm to which they were randomized. Patients continue to be followed for the clinical endpoints of time to distant failure, which typically would be the appearance of a positive bone scan, and for overall survival. P. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 22 april 2009 13:49 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 *DJ Dendreon Raised To Buy From Neutral By Merriman Curhan (END) Dow Jones NewswiresApril 22, 2009 01:03 ET (05:03 GMT)Copyright (c) 2009 Dow Jones & Company, Inc.- - 01 03 AM EDT 04-22-09Dirk Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 26 april 2009 20:10 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 seekingalpha.com/article/131596-is-de...Ik heb iig nog een plukje bijgekocht voor het weekend. Worden mooie weken zoals je kunt lezen. Suc6 allen. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 26 april 2009 20:17 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:spvthijs schreef:seekingalpha.com/article/131596-is-de...Ik heb iig nog een plukje bijgekocht voor het weekend. Worden mooie weken zoals je kunt lezen. Suc6 allen.ga je nu ook hier schelden? word nog leuk dan Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 27 april 2009 17:09 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Iig ben ik blij met de 8% voor vandaag! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 april 2009 16:36 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Whats happening???? Gaat als een trein! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 april 2009 17:07 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:spvthijs schreef:Whats happening???? Gaat als een trein!Over een paar uur de cijfers (20.20 uur)P. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 april 2009 17:48 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 agonist, D-3263, in Benign Prostatic Hyperplasia-- Data Presented at American Urological Association Annual Meeting --SEATTLE and CHICAGO, IL, April 28, 2008 - Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce BPH alone and in combination with finasteride, a current treatment for BPH.The abstract (#1408), "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia" is being presented at the American Urological Association's (AUA) 2009 Annual Meeting in Chicago, IL, today in a poster session from 10:30 a.m. to 12:30 p.m. CDT. In a preclinical study, BPH was induced in rats through subcutaneous injection of testosterone propionate (TP). One week after initiation of BPH, either D-3263, finasteride (an inhibitor of the enzyme 5-alpha-reductase) or a combination of the two agents was administered daily for two weeks. Following treatment, blood was sampled, prostates were collected and weighed, and tissue sections were examined histologically.Rats with TP-induced BPH who were treated with D-3263, finasteride or a combination of the two, had a significant reduction (p=0.004) of mean prostate weight and prostate hyperplasia with evidence of a dose response. In addition, the highest dose of D-3263 given in combination with finasteride resulted in lower prostate weights than either agent given alone, suggesting a potential additive effect. BPH-induced animals showed increases in dihydrotestosterone (DHT) concentrations in the plasma, levels of which were reduced in animals treated with D-3263, finasteride or a combination of the two. While finasteride is a known inhibitor of 5-alpha reductase, the enzyme that converts testosterone to DHT, D-3263 is not an inhibitor of this enzyme suggesting that the two agents may act by different means to affect androgen metabolism and prostate hyperplasia."BPH is a condition that affects a significant number of men, and based on the preclinical data announced today demonstrating the drug's ability to reduce the size and weight of the prostate, we believe that D-3263 may be able to impact this disease," said David Urdal, Ph.D., chief scientific officer of Dendreon. "We are also exploring the role of TRPM8 in cancer, given that TRPM8 is upregulated on cancer cells. A Phase 1 clinical trial to evaluate this molecule against multiple types of solid tumors has been recently initiated."About TRPM8TRPM8 (also known as TRPP8) was identified through Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures and small-molecule agonists and belongs to the melastatin subfamily-one of seven subfamilies of TRP proteins. In normal human tissues, TRPM8 is expressed predominantly in the prostate, a gland in the male reproductive system. It is over-expressed in prostate hyperplasia and multiple types of cancer including prostate cancer, breast cancer, colon cancer and lung cancer. In recent years, it has emerged that TRP channels play a diverse and key role in cell biology and in pathology. Dendreon has synthesized small molecule agonists including D3263 that activate the TRPM8 ion channel and induce cell death.About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as BPH. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a marketing license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a marketing license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.Contact Information:Jennifer Cook WilliamsInvestor RelationsDendreon Corporation206-829-1500Katherine StuelandWeissComm Partners Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 april 2009 18:15 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Posted by: Preciouslife1 Date: Tuesday, April 28, 2009 10:28:25 AM In reply to: None Post # of 76798 David Miller, BSR David is on CNBC right now on DNDN subject fyinet toen spike begon Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 28 april 2009 18:24 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:crackedtooth schreef:Posted by: Preciouslife1 Date: Tuesday, April 28, 2009 10:28:25 AM In reply to: None Post # of 76798 David Miller, BSR David is on CNBC right now on DNDN subject fyinet toen spike begonih.fotothing.com/86727.jpg Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.